XGN

Exagen Inc.

Price Chart

Latest Quote

$4.25

-0.05 (-1.16%)

Current Price

Previous Close	$4.30
Open	$4.30
Day High	$4.38
Day Low	$4.17
Volume	166,551

Fetched: 2026-07-16T22:04:12

Stock Information

Shares Outstanding	24.16M
Total Debt	$27.15M
Cash Equivalents	$21.51M
Revenue	$68.38M
Net Income	$-20.17M
Sector	Healthcare
Industry	Diagnostics & Research
Market Cap	$106.06M
EPS (TTM)	$-0.93
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$111.69M
Sales	$68.38M
Income	$-20.17M
Book/sh	$0.60
Cash/sh	$0.89
Employees	216

Financial Ratios

Quick Ratio	2.97
Current Ratio	3.47
Debt/Eq	188.10

Returns & Margins

ROA	-19.13%
ROE	-193.58%
Gross Margin	58.32%
Operating Margin	-19.73%
Profit Margin	-29.49%

Ownership

Insider Ownership	27.91%
Institutional Ownership	52.63%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-10.21
P/S	1.55
P/B	7.33

Analyst Data

Recommendation	strong_buy
Target Price	$8.57

Technical Indicators

SMA20	$4.48
SMA50	$4.31
SMA200	$5.58
RSI	46.44
ATR	0.3076

Shares Float	13.81M
Short Float	3.72%
Short Ratio	2.77
Volatility	2.02
Rel Volume	0.75

Performance History

Week	-1.35%
Month	-3.52%
Quarter	+43.93%
6 Months	-13.75%
YTD	-27.32%
Year	-37.29%
3 Years	+55.67%
5 Years	-69.72%
10 Years	-74.34%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$4.39	159,900
2026-07-16	$4.25	166,600
2026-07-15	$4.30	169,500
2026-07-14	$4.09	349,500
2026-07-13	$4.14	281,300
2026-07-10	$4.45	95,800
2026-07-09	$4.62	179,700
2026-07-08	$4.36	489,700
2026-07-07	$4.80	286,100
2026-07-06	$4.40	145,700
2026-07-02	$4.54	127,800
2026-07-01	$4.71	83,000
2026-06-30	$4.65	197,200
2026-06-29	$4.75	151,800
2026-06-26	$4.58	404,600
2026-06-25	$4.64	182,200
2026-06-24	$4.52	122,200
2026-06-23	$4.36	104,200
2026-06-22	$4.42	258,600
2026-06-18	$4.54	304,700

About Exagen Inc.

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

📰 Latest News

Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets

Simply Wall St. • 2026-06-19T04:33:34Z

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

Zacks • 2026-05-28T13:55:01Z

The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Simply Wall St. • 2026-05-14T11:15:52Z

Exagen (XGN) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-12T18:16:06Z

Exagen Inc. Q1 2026 Earnings Call Summary

Moby • 2026-05-12T12:30:00Z

Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...

GuruFocus.com • 2026-05-12T07:02:52Z

Exagen Q1 Earnings Call Highlights

MarketBeat • 2026-05-11T17:09:50Z

Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses

InvestorsHub • 2026-05-11T14:59:14Z

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Zacks • 2026-05-11T13:20:06Z

AtriCure (ATRC) Reports Break-Even Earnings for Q1

Zacks • 2026-05-05T21:15:02Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$27,776,000	$22,529,000	$23,092,000	$24,214,000
Cost Of Revenue	$27,776,000	$22,529,000	$23,092,000	$24,214,000
Total Revenue	$66,575,000	$55,641,000	$52,548,000	$45,563,000
Operating Revenue	$66,575,000	$55,641,000	$52,548,000	$45,563,000
Expenses
Interest Expense	$4,318,000	$2,234,000	$2,335,000	$2,448,000
Total Expenses	$80,645,000	$69,277,000	$75,385,000	$86,108,000
Other Income Expense	$-1,801,000	-	-	$-5,506,000
Net Non Operating Interest Income Expense	$-4,029,000	$-1,467,000	$-819,000	$-1,618,000
Interest Expense Non Operating	$4,318,000	$2,234,000	$2,335,000	$2,448,000
Operating Expense	$52,869,000	$46,748,000	$52,293,000	$61,894,000
Other Non Operating Income Expenses	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-19,951,000	$-15,115,000	$-23,689,000	$-47,387,000
Net Interest Income	$-4,029,000	$-1,467,000	$-819,000	$-1,618,000
Interest Income	$289,000	$767,000	$1,516,000	$830,000
Normalized Income	$-18,528,210	$-15,115,000	$-23,689,000	$-41,914,036
Net Income From Continuing And Discontinued Operation	$-19,951,000	$-15,115,000	$-23,689,000	$-47,387,000
Total Operating Income As Reported	$-14,070,000	$-13,636,000	$-22,837,000	$-46,051,000
Net Income Common Stockholders	$-19,951,000	$-15,115,000	$-23,689,000	$-47,387,000
Net Income	$-19,951,000	$-15,115,000	$-23,689,000	$-47,387,000
Net Income Including Noncontrolling Interests	$-19,951,000	$-15,115,000	$-23,689,000	$-47,387,000
Net Income Continuous Operations	$-19,951,000	$-15,115,000	$-23,689,000	$-47,387,000
Pretax Income	$-19,900,000	$-15,103,000	$-23,656,000	$-47,669,000
Special Income Charges	$-295,000	$0	$0	$-5,506,000
Interest Income Non Operating	$289,000	$767,000	$1,516,000	$830,000
Operating Income	$-14,070,000	$-13,636,000	$-22,837,000	$-40,545,000
Gross Profit	$38,799,000	$33,112,000	$29,456,000	$21,349,000
Per Share
Diluted EPS	$-0.93	$-0.83	$-1.34	$-2.77
Basic EPS	$-0.93	$-0.83	$-1.34	$-2.77
Other
Tax Effect Of Unusual Items	$-378,210	$0	$0	$-33,036
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-11,663,000	$-11,145,000	$-19,153,000	$-38,158,000
Total Unusual Items	$-1,801,000	$0	$0	$-5,506,000
Total Unusual Items Excluding Goodwill	$-1,801,000	$0	$0	$-5,506,000
Reconciled Depreciation	$2,118,000	$1,724,000	$2,168,000	$1,557,000
EBITDA (Bullshit earnings)	$-13,464,000	$-11,145,000	$-19,153,000	$-43,664,000
EBIT	$-15,582,000	$-12,869,000	$-21,321,000	$-45,221,000
Diluted Average Shares	$21,558,245	$18,203,044	$17,679,467	$17,082,348
Basic Average Shares	$21,558,245	$18,203,044	$17,679,467	$17,082,348
Diluted NI Availto Com Stockholders	$-19,951,000	$-15,115,000	$-23,689,000	$-47,387,000
Tax Provision	$51,000	$12,000	$33,000	$-282,000
Other Special Charges	$295,000	-	-	-
Gain On Sale Of Security	$-1,506,000	-	-	-
Research And Development	$6,254,000	$5,375,000	$4,865,000	$9,876,000
Selling General And Administration	$46,615,000	$41,373,000	$47,428,000	$52,018,000
Impairment Of Capital Assets	-	-	$0	$5,506,000

Fetched: 2026-07-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$17,449,000	$9,540,000	$22,694,000	$42,460,000
Total Assets	$58,022,000	$44,689,000	$56,944,000	$86,221,000
Total Non Current Assets	$9,129,000	$8,234,000	$9,103,000	$13,610,000
Other Non Current Assets	$756,000	$550,000	$616,000	$528,000
Current Assets	$48,893,000	$36,455,000	$47,841,000	$72,611,000
Other Current Assets	$38,000	$30,000	$1,926,000	$236,000
Prepaid Assets	$5,780,000	$6,554,000	$2,871,000	$3,907,000
Receivables	$10,855,000	$7,835,000	$6,551,000	$6,077,000
Accounts Receivable	$10,855,000	$7,835,000	$6,551,000	$6,077,000
Cash Cash Equivalents And Short Term Investments	$32,220,000	$22,036,000	$36,493,000	$62,391,000
Cash And Cash Equivalents	$32,220,000	$22,036,000	$36,493,000	$62,391,000
Allowance For Doubtful Accounts Receivable	-	$-7,800	$-6,600	-
Gross Accounts Receivable	-	$7,842,800	$6,557,600	-
Goodwill And Other Intangible Assets	-	-	-	$0
Debt
Total Debt	$25,706,000	$23,206,000	$23,231,000	$35,201,000
Long Term Debt And Capital Lease Obligation	$22,702,000	$21,486,000	$21,991,000	$33,271,000
Long Term Debt	$22,264,000	$19,822,000	$19,231,000	$28,778,000
Current Debt And Capital Lease Obligation	$3,004,000	$1,720,000	$1,240,000	$1,930,000
Current Debt	$643,000	$423,000	$264,000	$190,000
Other Current Borrowings	$643,000	$423,000	$264,000	$190,000
Liabilities
Total Liabilities Net Minority Interest	$40,573,000	$35,149,000	$34,250,000	$43,761,000
Total Non Current Liabilities Net Minority Interest	$26,414,000	$21,643,000	$22,348,000	$34,138,000
Other Non Current Liabilities	$1,960,000	$157,000	$357,000	$867,000
Derivative Product Liabilities	$1,752,000	$0	-	-
Current Liabilities	$14,159,000	$13,506,000	$11,902,000	$9,623,000
Current Deferred Liabilities	$675,000	$733,000	-	-
Payables And Accrued Expenses	$10,480,000	$11,053,000	$10,662,000	$7,248,000
Payables	$4,153,000	$4,137,000	$3,131,000	$3,046,000
Accounts Payable	$4,153,000	$4,137,000	$3,131,000	$3,046,000
Other Current Liabilities	-	-	$302,000	$445,000
Interest Payable	-	-	$139,000	$142,000
Non Current Deferred Liabilities	-	-	-	$0
Non Current Deferred Taxes Liabilities	-	-	-	$0
Equity
Common Stock Equity	$17,449,000	$9,540,000	$22,694,000	$42,460,000
Total Equity Gross Minority Interest	$17,449,000	$9,540,000	$22,694,000	$42,460,000
Stockholders Equity	$17,449,000	$9,540,000	$22,694,000	$42,460,000
Retained Earnings	$-314,282,000	$-294,331,000	$-279,216,000	$-255,527,000
Other
Ordinary Shares Number	$22,911,575	$17,640,328	$17,045,954	$16,549,984
Share Issued	$22,911,575	$17,640,328	$17,045,954	$16,549,984
Tangible Book Value	$17,449,000	$9,540,000	$22,694,000	$42,460,000
Invested Capital	$40,356,000	$29,785,000	$42,189,000	$71,428,000
Working Capital	$34,734,000	$22,949,000	$35,939,000	$62,988,000
Capital Lease Obligations	$2,799,000	$2,961,000	$3,736,000	$6,233,000
Total Capitalization	$39,713,000	$29,362,000	$41,925,000	$71,238,000
Additional Paid In Capital	$331,708,000	$303,853,000	$301,893,000	$297,970,000
Capital Stock	$23,000	$18,000	$17,000	$17,000
Common Stock	$23,000	$18,000	$17,000	$17,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$438,000	$1,664,000	$2,760,000	$4,493,000
Current Deferred Revenue	$675,000	$733,000	-	-
Current Capital Lease Obligation	$2,361,000	$1,297,000	$976,000	$1,740,000
Current Accrued Expenses	$6,327,000	$6,916,000	$7,531,000	$4,202,000
Net PPE	$8,373,000	$7,684,000	$8,487,000	$13,082,000
Accumulated Depreciation	$-7,144,000	$-6,012,000	$-5,769,000	$-5,124,000
Gross PPE	$15,517,000	$13,696,000	$14,256,000	$18,206,000
Leases	$3,308,000	$3,259,000	$3,316,000	$5,223,000
Construction In Progress	$294,000	$1,543,000	$59,000	$1,382,000
Other Properties	$9,673,000	$6,676,000	$8,598,000	$10,021,000
Machinery Furniture Equipment	$2,242,000	$2,218,000	$2,283,000	$1,580,000
Properties	$0	$0	$0	$0
Treasury Shares Number	-	-	$0	-
Goodwill	-	-	-	$0
Buildings And Improvements	-	-	-	$4,885,000

Fetched: 2026-07-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-14,266,000	$-13,794,000	$-15,290,000	$-36,462,000
Operating Activities
Operating Cash Flow	$-13,625,000	$-13,279,000	$-14,462,000	$-32,144,000
Cash Flow From Continuing Operating Activities	$-13,625,000	$-13,279,000	$-14,462,000	$-32,144,000
Operating Gains Losses	$1,801,000	$111,000	$189,000	-
Investing Activities
Capital Expenditure	$-641,000	$-515,000	$-828,000	$-4,318,000
Investing Cash Flow	$-626,000	$-515,000	$-804,000	$-4,318,000
Cash Flow From Continuing Investing Activities	$-626,000	$-515,000	$-804,000	$-4,318,000
Net Other Investing Changes	-	-	-	-
Financing Activities
Issuance Of Capital Stock	$22,025,000	$0	-	$0
Financing Cash Flow	$24,435,000	$-663,000	$-10,632,000	$-489,000
Cash Flow From Continuing Financing Activities	$24,435,000	$-663,000	$-10,632,000	$-489,000
Net Other Financing Charges	$-869,000	-	-	$-239,000
Net Common Stock Issuance	$22,025,000	$0	-	$0
Common Stock Issuance	$22,025,000	$0	-	$0
Other
Repayment Of Debt	$-20,791,000	$-861,000	$-10,938,000	$-696,000
Issuance Of Debt	$23,672,000	$0	-	-
Interest Paid Supplemental Data	$2,987,000	$1,719,000	$1,737,000	$1,732,000
Income Tax Paid Supplemental Data	$35,000	$32,000	-	-
End Cash Position	$32,420,000	$22,236,000	$36,693,000	$62,591,000
Beginning Cash Position	$22,236,000	$36,693,000	$62,591,000	$99,542,000
Changes In Cash	$10,184,000	$-14,457,000	$-25,898,000	$-36,951,000
Proceeds From Stock Option Exercised	$398,000	$198,000	$306,000	$446,000
Net Issuance Payments Of Debt	$2,881,000	$-861,000	$-10,938,000	$-696,000
Net Long Term Debt Issuance	$2,881,000	$-861,000	$-10,938,000	$-696,000
Long Term Debt Payments	$-20,791,000	$-861,000	$-10,938,000	$-696,000
Long Term Debt Issuance	$23,672,000	$0	-	-
Net PPE Purchase And Sale	$-626,000	$-515,000	$-804,000	$-4,318,000
Sale Of PPE	$15,000	$0	$24,000	$0
Purchase Of PPE	$-641,000	$-515,000	$-828,000	$-4,318,000
Change In Working Capital	$-1,981,000	$-3,076,000	$325,000	$1,670,000
Change In Other Working Capital	$-58,000	$733,000	-	-
Change In Other Current Liabilities	$-1,096,000	$-976,000	$-1,010,000	$-854,000
Change In Other Current Assets	$792,000	$63,000	$-101,000	$-47,000
Change In Payables And Accrued Expense	$293,000	$175,000	$2,564,000	$-501,000
Change In Accrued Expense	$251,000	$-133,000	$2,497,000	$-1,402,000
Change In Payable	$42,000	$308,000	$67,000	$901,000
Change In Account Payable	$42,000	$308,000	$67,000	$901,000
Change In Prepaid Assets	$1,108,000	$-1,787,000	$-654,000	$-505,000
Change In Receivables	$-3,020,000	$-1,284,000	$-474,000	$3,577,000
Changes In Account Receivables	$-3,020,000	$-1,284,000	$-474,000	$3,577,000
Other Non Cash Items	$2,230,000	$1,425,000	$2,928,000	$1,715,000
Stock Based Compensation	$2,158,000	$1,763,000	$3,617,000	$4,704,000
Depreciation Amortization Depletion	$2,118,000	$1,724,000	$2,168,000	$1,557,000
Depreciation And Amortization	$2,118,000	$1,724,000	$2,168,000	$1,557,000
Gain Loss On Investment Securities	$1,506,000	-	-	-
Net Income From Continuing Operations	$-19,951,000	$-15,115,000	$-23,689,000	$-47,387,000
Asset Impairment Charge	-	-	$0	$5,903,000
Deferred Tax	-	-	$0	$-306,000
Deferred Income Tax	-	-	$0	$-306,000

Fetched: 2026-07-16